trending Market Intelligence /marketintelligence/en/news-insights/trending/eobe24ez8pao3ypwkdjd9w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Supernus wins patent infringement ruling against TWi regarding epilepsy drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Supernus wins patent infringement ruling against TWi regarding epilepsy drug

Supernus Pharmaceuticals Inc. said a U.S. appeals court upheld a previous patent infringement ruling against TWi Pharmaceuticals Inc. regarding its epilepsy drug.

The U.S. Court of Appeals for the Federal Circuit affirmed the New Jersey District Court's decision that TWi infringed on three Supernus patents related to anti-epileptic drug Oxtellar XR.

The appeals court said the three patents are valid. The decision ends all outstanding litigations and generic challenges to Oxtellar XR.

Rockville, Md.-based Supernus previously won a similar appeals decision against Teva Pharmaceutical Industries Ltd's Actavis.

Supernus said it plans to expand Oxtellar XR's indication to include use as a single therapy for partial seizures of epilepsy as well as the development program for bipolar disorder.

The company holds eight issued patents for Oxtellar XR which will expire in 2027 at the earliest.